Ignite Creation Date:
2025-12-25 @ 12:31 AM
Ignite Modification Date:
2026-01-10 @ 3:11 PM
Study NCT ID:
NCT05936567
Status:
COMPLETED
Last Update Posted:
2025-10-15
First Post:
2023-06-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014581', 'term': 'Urticaria'}, {'id': 'D000080223', 'term': 'Chronic Urticaria'}, {'id': 'D000799', 'term': 'Angioedema'}, {'id': 'D011537', 'term': 'Pruritus'}], 'ancestors': [{'id': 'D017445', 'term': 'Skin Diseases, Vascular'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D006969', 'term': 'Hypersensitivity, Immediate'}, {'id': 'D006967', 'term': 'Hypersensitivity'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D012877', 'term': 'Skin Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 136}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2023-07-31', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-10', 'completionDateStruct': {'date': '2025-10-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-10-14', 'studyFirstSubmitDate': '2023-06-26', 'studyFirstSubmitQcDate': '2023-07-06', 'lastUpdatePostDateStruct': {'date': '2025-10-15', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2023-07-07', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-02-28', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from baseline in the urticaria activity score (UAS7)', 'timeFrame': '12 Weeks', 'description': 'Defined as the 7-day sum of the individual, daily recorded scores for HSS and ISS, at week 12. UAS scores range from 0-42; with higher scores reflecting greater disease activity.'}], 'secondaryOutcomes': [{'measure': 'Proportion of participants who achieve UAS7 ≤ 6 (controlled disease) at Week 12', 'timeFrame': '12 Weeks', 'description': 'Defined as the 7-day sum of the individual, daily recorded scores for HSS and ISS, at week 12. UAS scores range from 0-42; with higher scores reflecting greater disease activity.'}, {'measure': 'Time to first achievement of UAS7 ≤ 6 (controlled disease) during the PC period', 'timeFrame': '12 Weeks', 'description': 'Defined as the 7-day sum of the individual, daily recorded scores for HSS and ISS. UAS scores range from 0-42; with higher scores reflecting greater disease activity.'}, {'measure': 'Proportion of participants with UAS7 = 0 at Week 12.', 'timeFrame': '12 Weeks', 'description': 'Defined as the 7-day sum of the individual, daily recorded scores for HSS and ISS, at week 12. UAS scores range from 0-42; with higher scores reflecting greater disease activity.'}]}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Urticaria', 'Chronic Spontaneous Urticaria', 'Chronic Idiopathic Urticaria', 'Hives', 'Angioedema', 'Pruritis']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.incyteclinicaltrials.com/study/?id=INCB54707-207&SearchTerm=INCB54707-207&Latitude=&Longitude=&LocationName=&conditions=&Status=&phases=&AgeRanges=&gender=&StudyTypes=&AttachmentTypes=&MileRadius=100&PageIndex=0&PageSize=10&SortField=&SortOrder=&hasResults=', 'label': 'Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria'}]}, 'descriptionModule': {'briefSummary': 'This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n* CSU diagnosis for ≥ 3 months prior to screening.\n* CSU refractory to second-generation H1 antihistamines\n* Participants must have been on a stable dose of second-generation H1 antihistamine, and must agree to maintain the stable dose of second-generation H1 antihistamine throughout study.\n* Willingness and ability to comply with the study Protocol and procedures.\n* Further inclusion criteria apply\n\nExclusion Criteria:\n\n* Treatment with an anti-IgE biologic (eg, omalizumab) within 8 weeks prior to screening.\n* Clearly defined underlying etiology for chronic urticarias other than CSU\n* Other cutaneous or systemic diseases with chronic itching or with symptoms of urticaria or angioedema.\n* Women who are pregnant (or who are considering pregnancy) or breastfeeding.\n* Concurrent or history of Thrombocytopenia, coagulopathy, or platelet dysfunction, Venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure (NYHA Class III or IV), cerebrovascular accident, MI, coronary stenting, or CABG surgery, other significant cardiovascular diseases or uncontrolled hypertension\n* Recipient of an organ transplant that requires continued immunosuppression.\n* Any malignancies or history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ.\n* Chronic or recurrent infectious disease.\n* Further exclusion criteria apply.'}, 'identificationModule': {'nctId': 'NCT05936567', 'briefTitle': 'Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria', 'organization': {'class': 'INDUSTRY', 'fullName': 'Incyte Corporation'}, 'officialTitle': 'A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria', 'orgStudyIdInfo': {'id': 'INCB54707-207'}, 'secondaryIdInfos': [{'id': '2022-503062-72-00', 'type': 'REGISTRY', 'domain': 'EU CT Number'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Povorcitinib Dose A', 'description': 'Participants will receive dose A of povorcitinib for a 12 week period, followed by dose A for an additional 24 week period.', 'interventionNames': ['Drug: Povorcitinib']}, {'type': 'EXPERIMENTAL', 'label': 'Povorcitinib Dose B', 'description': 'Participants will receive dose B of povorcitinib for a 12 week period, followed by dose B for an additional 24 week period.', 'interventionNames': ['Drug: Povorcitinib']}, {'type': 'EXPERIMENTAL', 'label': 'Povorcitinib Dose C', 'description': 'Participants will receive dose C of povorcitinib for a 12 week period, followed by dose C for an additional 24 week period.', 'interventionNames': ['Drug: Povorcitinib']}, {'type': 'EXPERIMENTAL', 'label': 'Placebo followed by Povorcitinib Dose A, B, or C', 'description': 'Participants will receive placebo for a 12 week period, followed by randomization to either Dose A, Dose B, or Dose C for an additional 24 week period.', 'interventionNames': ['Drug: Povorcitinib', 'Drug: Placebo']}], 'interventions': [{'name': 'Povorcitinib', 'type': 'DRUG', 'description': 'oral; tablet', 'armGroupLabels': ['Placebo followed by Povorcitinib Dose A, B, or C', 'Povorcitinib Dose A', 'Povorcitinib Dose B', 'Povorcitinib Dose C']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'oral; tablet', 'armGroupLabels': ['Placebo followed by Povorcitinib Dose A, B, or C']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35209', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'Clinical Research Center of Alabama', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '35244', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'Cahaba Dermatology', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '85260', 'city': 'Scottsdale', 'state': 'Arizona', 'country': 'United States', 'facility': 'Foothills Research Center', 'geoPoint': {'lat': 33.50921, 'lon': -111.89903}}, {'zip': '72205', 'city': 'Little Rock', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Little Rock Allergy Asthma, Pa Clinical Research Center Lraac', 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'zip': '72117', 'city': 'North Little Rock', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Arkansas Research Trials', 'geoPoint': {'lat': 34.76954, 'lon': -92.26709}}, {'zip': '92708', 'city': 'Fountain Valley', 'state': 'California', 'country': 'United States', 'facility': 'First Oc Dermatology', 'geoPoint': {'lat': 33.70918, 'lon': -117.95367}}, {'zip': '92663', 'city': 'Newport Beach', 'state': 'California', 'country': 'United States', 'facility': 'Newport Native Md', 'geoPoint': {'lat': 33.61891, 'lon': -117.92895}}, {'zip': '93551', 'city': 'Palmdale', 'state': 'California', 'country': 'United States', 'facility': 'Antelope Valley Clinical Trials Lancaster Office', 'geoPoint': {'lat': 34.57943, 'lon': -118.11646}}, {'zip': '94063', 'city': 'Redwood City', 'state': 'California', 'country': 'United States', 'facility': 'Allergy and Asthma Consultants, Pc', 'geoPoint': {'lat': 37.48522, 'lon': -122.23635}}, {'zip': '83706', 'city': 'Boise', 'state': 'Idaho', 'country': 'United States', 'facility': 'Treasure Valley Medical Research', 'geoPoint': {'lat': 43.6135, 'lon': -116.20345}}, {'zip': '61761', 'city': 'Normal', 'state': 'Illinois', 'country': 'United States', 'facility': 'Midwest Allergy Sinus Asthma, Sc', 'geoPoint': {'lat': 40.5142, 'lon': -88.99063}}, {'zip': '70115', 'city': 'New Orleans', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Delricht Research', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '48103', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'David Fivenson, Md, Dermatology, Pllc', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '48084', 'city': 'Troy', 'state': 'Michigan', 'country': 'United States', 'facility': 'Revival Research Institute, Llc Troy', 'geoPoint': {'lat': 42.60559, 'lon': -83.14993}}, {'zip': '63141', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'The Clinical Research Center Crc, Llc', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '43235', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Optimed Research Ltd', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '73170', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Central Sooner Research', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '74136', 'city': 'Tulsa', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Vital Prospects Clinical Research Institute, Pc Vpcri', 'geoPoint': {'lat': 36.15398, 'lon': -95.99277}}, {'zip': '18249', 'city': 'Sugarloaf', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Dermdox Center For Dermatology', 'geoPoint': {'lat': 41.98343, 'lon': -76.12083}}, {'zip': '29407', 'city': 'Charleston', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Allergy and Asthma Center of Charleston', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'zip': '78212', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Rainey and Finklea Dermatology', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '98225', 'city': 'Bellingham', 'state': 'Washington', 'country': 'United States', 'facility': 'Bellingham Asthma, Allergy Immunology Clinic', 'geoPoint': {'lat': 48.75955, 'lon': -122.48822}}, {'zip': '12200', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '01307', 'city': 'Dresden', 'country': 'Germany', 'facility': 'Universitaetsklinikum Carl Gustav Carus Tu Dresden', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '60590', 'city': 'Frankfurt', 'country': 'Germany', 'facility': 'Universitatsklinikum Frankfurt', 'geoPoint': {'lat': 49.68333, 'lon': 10.53333}}, {'zip': '22391', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Mensingderma Research Gmbh', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '24105', 'city': 'Kiel', 'country': 'Germany', 'facility': 'Universitaetsklinikum Schleswig-Holstein - Campus Kiel', 'geoPoint': {'lat': 54.32133, 'lon': 10.13489}}, {'zip': '04103', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Universitatsklinikum Leipzig Aor', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '55131', 'city': 'Mainz', 'country': 'Germany', 'facility': 'Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii', 'geoPoint': {'lat': 49.98185, 'lon': 8.28008}}, {'zip': '49074', 'city': 'Osnabrück', 'country': 'Germany', 'facility': 'Klifos - Klinische Forschung Osnabruck', 'geoPoint': {'lat': 52.27264, 'lon': 8.0498}}, {'zip': '72076', 'city': 'Tübingen', 'country': 'Germany', 'facility': 'Universitats-Hautklink Tubingen', 'geoPoint': {'lat': 48.52266, 'lon': 9.05222}}, {'zip': '15-375', 'city': 'Bialystok', 'country': 'Poland', 'facility': 'Specderm Poznanska', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '40-081', 'city': 'Katowice', 'country': 'Poland', 'facility': 'Centrum Medyczne Pratia Katowice I', 'geoPoint': {'lat': 50.2597, 'lon': 19.02173}}, {'zip': '20-552', 'city': 'Lublin', 'country': 'Poland', 'facility': 'Centrum Alergologii Sp Z.O.O', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'zip': '45-401', 'city': 'Opole', 'country': 'Poland', 'facility': 'University Clinical Hospital', 'geoPoint': {'lat': 50.67119, 'lon': 17.92604}}, {'zip': '60-529', 'city': 'Poznan', 'country': 'Poland', 'facility': 'Solumed Centrum Medyczne', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '60-693', 'city': 'Poznan', 'country': 'Poland', 'facility': 'Specjalistyczny Nzoz Alergologia Plus', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '58-100', 'city': 'Swidnica', 'country': 'Poland', 'facility': 'DC-MED', 'geoPoint': {'lat': 50.84378, 'lon': 16.48859}}, {'zip': '02-507', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych Administracji', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '02-793', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Etg Warszawa', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '02-953', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Klinika Ambroziak', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '50-449', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'Melita Medical Sp. Z O. O.', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Incyte Corporation', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}